Diagnostik und histologische Besonderheiten von Systemvaskulitiden – Teil 2

Zusammenfassung

Unter dem Begriff der Systemvaskulitiden werden diejenigen Entzündungen zusammengefasst, die zum einen neben der Hautbeteiligung auch eine Vielfalt an Organbeteiligungen aufweisen können, welche durch einen möglicherweise lebensbedrohlichen Verlauf gekennzeichnet sind, als auch die Entzündungen an den großen Gefäßen (Aorta, Organgefäßen). Sui generis ergeben sich hierdurch andere Anforderungen an die Diagnostik, die Therapie und das Therapiemonitoring dieser Patienten und die Notwendigkeit eines engen interdisziplinären Managements dieser Erkrankungen zwischen den beteiligten Fachrichtungen, insbesondere Dermatologie und Rheumatologie. Die Rolle des Dermatologen ist in Bezug auf diese Vaskulitiden die des „Weichenstellers“ und er ist für die Unterscheidung der rein kutanen Vaskulitiden von Vaskulitiden mit potenziell lebensbedrohlichem Verlauf durch Multiorganbeteiligung verantwortlich. Daher werden in Teil 2 dieser Weiterbildungsreihe die dermatologisch relevanten Charakteristika der sog. Systemvaskulitiden schwerpunktmäßig dargestellt, aktuelle Begriffe und Namensänderungen diskutiert und histologische Befunde präsentiert.

Abstract

System vasculitis sums up all forms of vasculitis involving the skin and other organs that bear the risk of a life-threatening course and may involve large vessels as the aorta or large organ vessels. In these cases the demands concerning diagnostic procedures, therapy as well as therapy monitoring are challenging and require a close interdisciplinary teamwork with other disciplines such as dermatology and rheumatology. The dermatologist himself plays the role of a pointsman – he is responsible for the differentiation between vasculitis of the skin and other forms of vasculitis with a potential life-threatening course due to multi-organ involvement. In the second part of this training course, we focus on the relevant dermatologic criteria of system vasculitis. Furthermore, current terms and term changes as well as histological features are presented and discussed.

• Literatur

• 1 Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013; 17: 360-373
• 2 Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
• 3 Holle JU. ANCA-associated vasculitis. Internist 2015; 56: 41-50; quiz 51 – 52
• 4 Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990; 33: 1101-1107
• 5 Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-1100
• 6 Holle JU, Wieczorek S, Epplen JT et al. Genetischer Hintergrund der Vaskulitiden. Z Rheumatol 2011; 70: 198-204
• 7 Greco A, Rizzo MI, De Virgilio A et al. Churg-Strauss syndrome. Autoimmun Rev 2015; 14: 341-348
• 8 Groh M, Pagnoux C, Baldini C et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26: 545-553
• 9 Mahr A, Moosig F, Neumann T et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol 2014; 26: 16-23
• 10 Wegener F. On generalised septic vessel diseases. By Friedrich Wegener, 1937 (translation). Thorax 1987; 42: 918-919
• 11 Wright AC, Gibson LE, Davis DM. Cutaneous manifestations of pediatric granulomatosis with polyangiitis: a clinicopathologic and immunopathologic analysis. J Am Acad Dermatol 2015; 72: 859-867
• 12 Boucelma M, Hakem D, Ibrir M et al. Wegener’s Granulomatosis and necrotizing ulceration of the breast. One case report. Rev Med Interne 2005; 26: 155-157
• 13 Massone C, Felletti R, Noto S et al. Enlarging ulcers in the mouth and on the back. Granulomatosis with polyangiitis. Am J Dermatopathol 2015; 37: 293-294, 341 – 342
• 14 Barksdale SK, Hallahan CW, Kerr GS et al. Cutaneous pathology in Wegener’s granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. Am J Surg Pathol 1995; 19: 161-172
• 15 Daoud MS, Gibson LE, DeRemee RA et al. Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 1994; 31: 605-612
• 16 Comfere NI, Macaron NC, Gibson LE. Cutaneous manifestations of Wegener’s granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status. J Cutan Pathol 2007; 34: 739-747
• 17 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 277-301
• 18 Strauss L, Churg J, Zak FG. Cutaneous lesions of allergic granulomatosis; a histopathologic study. J Invest Dermatol 1951; 17: 349-359
• 19 Ishibashi M, Kudo S, Yamamoto K et al. Churg-Strauss syndrome with coexistence of eosinophilic vasculitis, granulomatous phlebitis and granulomatous dermatitis in bullous pemphigoid-like blisters. J Cutan Pathol 2011; 38: 290-294
• 20 Ratzinger G, Zankl J, Eisendle K et al. Eosinophilic leukocytoclastic vasculitis – a spectrum ranging from Wells’ syndrome to Churg-Strauss syndrome?. Eur J Dermatol 2014; 24: 603-610
• 21 Ratzinger G, Zankl J, Zelger B. Wells syndrome and its relationship to Churg-Strauss syndrome. Int J Dermatol 2013; 52: 949-954
• 22 Sunderkotter C, Pappelbaum KI, Ehrchen J. Cutaneous symptoms of various vasculitides. Hautarzt 2015; 66: 589-598
• 23 Ishibashi M, Kawahara Y, Chen KR. Spectrum of cutaneous vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a case series. Am J Dermatopathol 2015; 37: 214-221
• 24 Davis MD, Daoud MS, McEvoy MT et al. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997; 37: 199-203
• 25 Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-2935
• 26 Savage CO, Winearls CG, Evans DJ et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56: 467-483
• 27 Kallenberg CG. The diagnosis and classification of microscopic polyangiitis. J Autoimmun 2014; 48–49: 90-93
• 28 Greco A, De Virgilio A, Rizzo MI et al. Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches. Autoimmun Rev 2015; 14: 837-844
• 29 Kluger N, Pagnoux C, Guillevin L et al. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol 2008; 159: 615-620
• 30 Kawakami T, Soma Y, Saito C et al. Cutaneous manifestations in patients with microscopic polyangiitis: two case reports and a minireview. Acta Derm Venereol 2006; 86: 144-147
• 31 Csernok E. Stellenwert der Antineutrophilen zytoplasmatischen Antikörper (ANCA) in der Diagnostik von Vaskulitiden. Med Welt 2004; 55: 78-84
• 32 Biesen R, Burmester GR, Hiepe F. Rheumatoid factor or antinuclear antibodies as incidental finding. Internist (Berl) 2014; 55: 1157-1164
• 33 Hartung K, Seelig HP. Laboratory diagnostics of systemic autoimmune diseases. Part II: rheumatoid arthritis and vasculopathies. Z Rheumatol 2007; 66: 225-237; quiz 238
• 34 de Groot K, Reinhold-Keller E. Wegener’s granulomatosis and microscopic polyangiitis. Z Rheumatol 2009; 68: 49-63; quiz 64
• 35 Gomez-Moyano E, Vera Casaño A, Camacho J et al. Kawasaki disease complicated by cutaneous vasculitis and peripheral gangrene. J Am Acad Dermatol 2011; 64: e74-e75
• 36 Yellen ES, Gauvreau K, Takahashi M et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010; 125: e234-e241
• 37 Ness T, Auw-Hadrich C, Schmidt D. Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment. Ophthalmologe 2006; 103: 296-301
• 38 Schmidt D, Ness T. Giant cell arteritis (arteriitis temporalis, arteriitis cranialis). Ophthalmologe 2006; 103: 293-295
• 39 Wagner AD. Giant cell arteritis (temporal arteritis). Pathophysiology, immunology. Ophthalmologe 2006; 103: 302-307
• 40 Chang GY. Clinical recognition of varicella zoster virus vasculopathy. Eur Neurol 2012; 67: 297-299
• 41 Nagel MA, Mahalingam R, Cohrs RJ et al. Virus vasculopathy and stroke: an under-recognized cause and treatment target. Infect Disord Drug Targets 2010; 10: 105-111
• 42 Silver B, Nagel MA, Mahalingam R et al. Varicella zoster virus vasculopathy: a treatable form of rapidly progressive multi-infarct dementia after 2 years’ duration. J Neurol Sci 2012; 323: 245-247
• 43 Gilden D, Nagel M. Varicella Zoster Virus in Temporal Arteries of Patients With Giant Cell Arteritis. J Infect Dis 2015; 212 (Suppl. 01) 37-39
• 44 Nagel MA, Gilden D. Update on varicella zoster virus vasculopathy. Curr Infect Dis Rep 2014; 16: 407
• 45 Gilden D, Cohrs RJ, Mahalingam R et al. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009; 8: 731-740
• 46 Pisapia DJ, Lavi E. VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. Exp Mol Pathol 2016; 100: 114-115
• 47 Nagel MA, Cohrs RJ, Mahalingam R et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008; 70: 853-860
• 48 Gottlober P, Bezold G, Schaer A et al. Sneddon’s syndrome in a child. Br J Dermatol 2000; 142: 374-376
• 49 Frances C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139-143
• 50 Wohlrab J, Fischer M, Marsch WC. Current diagnosis of Sneddon syndrome. Dtsch Med Wochenschr 2001; 126: 725-728
• 51 Zelger B, Sepp N, Schmid KW et al. Life history of cutaneous vascular lesions in Sneddon’s syndrome. Hum Pathol 1992; 23: 668-675
• 52 Altenburg A, Mahr A, Maldini C et al. Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data. Ophthalmologe 2012; 109: 531-541
• 53 Kötter I. Update Morbus Behcet. Z Rheumatol 2012; 71: 760-764
• 54 Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus 1937. Clin Exp Rheumatol 2010; 28 (Suppl. 60) 2-5
• 55 Mat MC, Sevim A, Fresko I et al. Behcet’s disease as a systemic disease. Clin Dermatol 2014; 32: 435-442
• 56 Verity DH, Marr JE, Ohno S et al. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999; 54: 213-220
• 57 Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76
• 58 Fernandes SR, Singsen BH, Hoffman GS. Sarcoidosis and systemic vasculitis. Semin Arthritis Rheum 2000; 30: 33-46
• 59 Saparia T, Lundstrom RJ. Severe Coronary Vasculitis During a Systemic Lupus Erythematosus Flare Improved Angiographically With Immune-Suppressant Therapy. Circulation 2016; 133: 1048